SC Individualized dosage. Type 2 DM Recommended total daily starting dose: 10 u w/ meal(s) followed by individual dosage adjustments, once daily or bid w/ meal(s) alone or in combination w/ oral antidiabetics & bolus insulin. Type 1 DM Recommended starting dose: 60-70% of total daily insulin requirements once daily at meal time in combination w/ short- or rapid-acting insulin at the remaining meals followed by individual dosage adjustments.
Not to be administered IV or IM. Discontinue if any deterioration in cardiac symptoms occur. Hypo-/hyperglycaemia. Omission of meal or unplanned strenuous physical exercise; inadequate dosing &/or discontinuation of treatment; concomitant illness especially infections & fever; concomitant diseases in the kidney, liver or diseases affecting adrenal, pituitary or thyroid gland. Untreated hyperglycaemic events eventually lead to diabetic ketoacidosis. Temporary worsening of diabetic retinopathy. Insulin Ab formation. Patients w/ risk factors for development of cardiac failure. Perform continuous rotation of inj site to reduce risk of developing lipodystrophy & cutaneous amyloidosis. Monitor blood glucose after change in inj site from affected to unaffected area. Observe for signs & symptoms of heart failure, wt gain & oedema. Transfer from other insulin medicinal products. Concomitant use w/ thiazolidinediones. May impair ability to drive & operate machinery. Pregnancy & lactation. Higher risk for severe hypoglycaemia in childn 2-5 yr. Childn <2 yr.
A10AD06 - insulin degludec and insulin aspart ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Sign Out
